Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Memphasys Ltd ( (AU:MEM) ) has issued an update.
Memphasys Limited announced the resignation of Mr. Paul Wright as Non-Executive Director, who has been with the company since March 2020, contributing significantly to its progress. The company remains focused on the commercialisation of its Felix™ technology in early access markets, supported by a strong board with expertise in technology, commercialisation, and reproductive health, ensuring continued growth and strategic development.
More about Memphasys Ltd
Memphasys Limited (ASX: MEM) is a biotechnology company specializing in advanced reproductive biotechnology. The company develops medical devices, diagnostics, and proprietary media for human and animal applications, with flagship technologies such as the Felix™ and RoXsta™ Systems aimed at enhancing fertility outcomes worldwide.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$9.92M
For a thorough assessment of MEM stock, go to TipRanks’ Stock Analysis page.